Retinal diseases Flashcards
(118 cards)
AMD risk factors
age, smoking, +FHx, female, light iris, hyperopia, HTN, hyperchol
what is the difference of soft vs hard drusen?
Hard: nodular thickening of BM of RPE• Soft: focal PED (separation from Bruch’s)
drusen size?
Small 64 mic; med 64-124, large>124
DDX Geographic Atrophy
1) central areolar choroidal dystrophy2) Sorsby macular dystrophy3) NC macular dystrophy
what is Cuticular (Basal Laminar) Drusen?
Type of early hard drusen (age 30-40s)• Many small, uniform, demarcated drusen,better seen on FA with“stars-in-the-sky” appearance• May develop large vitelliform detachment
what is reticular drusen? (PSEUDODRUSEN)
• Interlacing network of 125-250um drusen• First appear in superotemporal macula• Better seen on red-free, NOT on FA /ICG• “Sawtooth” subretinal deposits on OCT
AREDS– Components?
Vitamins C & E, beta carotene, copper, zinc
AREDS study details
25% reduction in progression to advanced AMD– 19% reduction in VA loss over 5 yrs– Criteria?• Bilateral intermediate (many int or 1 large)• Unilateral advanced AMD (wet AMD or GA)– Avoid in smokers?• Beta carotene
AREDS 2 components
Antioxidants w/o beta carotene• Omega-3 fatty acid• Xanthophylls (zeaxanthine, lutein)
Framingham Eye Study:
6% in age >65• 20% in age>75
Choroidal Neovascularization (CNV)• Classificaton?
Type 1– Under RPEType 2– Between RPE + photoreceptorsType 3– Retinal angiomatous proliferations (RAP)
classic CNV - on FA definition
Early hyper + late leakage
occult CNV definition
Stippled/granular early hyper + late stain– 2 types: fibrovascular PED vs. lateleakage of undetermined source
CNV types?
Predominantly Classic (>49% classic)– Minimally Classic (
Retinal Angiomatous Proliferation (RAP) classification
Stage 1– Intraretinal NV / leakageStage 2– Subretinal NV + serous PEDStage 3– Choroidal NV + fibrovascular PED– FA: retinochoroidal anastamoses
what is Pegaptanib (Macugen)
pegylated anti-VEGF RNA aptamer• binds VEGF 165• 0.3mg
what is Ranibizumab (Lucentis)
its:48kD Fab of Mab (
Bevacizumab (Avastin)
full-length Mab + Fc• targets VEGF-A• 1.25mg, 2.5mg
Aflibercept (Eylea)
ligand-binding domain of VEGFR ½ + IgG Fc• binds VEGF-A & placental-like GF• 2mg, 4mg
PDT- Regular vs. Reduced fluence?
Regular: 600mW/cm2- Reduced: 300mW/cm2
Vision Study
Macugen q6wks x 48wks > sham– improved VA in all CNV
MARINA
Lucentis q4wks x 2yrs > sham– Minimally-classic or occult w/o classic CNV
ANCHOR
Lucentis q4wks x 2yrs > PDT q3mo PRN– Predominantly-classic CNV
PIER
Lucentis q4wks x 3 then q12wks– Steady decline after 3mo c/w q4wks